Exact Sciences Corp (NASDAQ: EXAS) kicked off on Monday, up 4.21% from the previous trading day, before settling in for the closing price of $52.91. Over the past 52 weeks, EXAS has traded in a range of $40.62-$79.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 43.88%. While this was happening, its average annual earnings per share was recorded -4.66%. With a float of $182.38 million, this company’s outstanding shares have now reached $185.08 million.
Let’s determine the extent of company efficiency that accounts for 6600 employees. In terms of profitability, gross margin is 72.1%, operating margin of -8.38%, and the pretax margin is -7.82%.
Exact Sciences Corp (EXAS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Exact Sciences Corp is 1.46%, while institutional ownership is 99.79%. The most recent insider transaction that took place on Nov 13 ’24, was worth 1,001,325. In this transaction President and CEO of this company bought 19,500 shares at a rate of $51.35, taking the stock ownership to the 1,074,191 shares. Before that another transaction happened on Oct 08 ’24, when Company’s EVP, GM, Precision Oncology sold 929 for $70.00, making the entire transaction worth $65,030. This insider now owns 12,758 shares in total.
Exact Sciences Corp (EXAS) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.43 earnings per share (EPS), lower than consensus estimate (set at -0.36) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.66% per share during the next fiscal year.
Exact Sciences Corp (NASDAQ: EXAS) Trading Performance Indicators
Take a look at Exact Sciences Corp’s (EXAS) current performance indicators. Last quarter, stock had a quick ratio of 1.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.78. Likewise, its price to free cash flow for the trailing twelve months is 103.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.17, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Exact Sciences Corp (EXAS)
Looking closely at Exact Sciences Corp (NASDAQ: EXAS), its last 5-days average volume was 2.54 million, which is a drop from its year-to-date volume of 2.64 million. As of the previous 9 days, the stock’s Stochastic %D was 82.87%. Additionally, its Average True Range was 3.01.
During the past 100 days, Exact Sciences Corp’s (EXAS) raw stochastic average was set at 39.73%, which indicates a significant decrease from 85.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 119.31% in the past 14 days, which was higher than the 70.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $64.50, while its 200-day Moving Average is $58.10. However, in the short run, Exact Sciences Corp’s stock first resistance to watch stands at $56.08. Second resistance stands at $57.01. The third major resistance level sits at $58.65. If the price goes on to break the first support level at $53.51, it is likely to go to the next support level at $51.87. Now, if the price goes above the second support level, the third support stands at $50.94.
Exact Sciences Corp (NASDAQ: EXAS) Key Stats
The company with the Market Capitalisation of 10.17 billion has total of 185,076K Shares Outstanding. Its annual sales at the moment are 2,500 M in contrast with the sum of -204,150 K annual income. Company’s last quarter sales were recorded 708,660 K and last quarter income was -38,240 K.
